阿替利珠单抗对比多西他赛治疗晚期非小细胞肺癌的长期生存:随机III期OAK研究结果
OAK研究为随机III期试验,晚期非小细胞肺癌患者按1:1随机接受阿替利珠单抗或多西他赛治疗,最少随访26个月后评估总生存。阿替利珠单抗组长期生存者(≥24个月)比例28%高于多西他赛组18%,阿替利珠单抗组应答者中77%为长期生存者,多西他赛组仅48%。结论:阿替利珠单抗持续提供优于多西他赛的持久生存获益,安全性可耐受。
要点
- 阿替利珠单抗组长期生存者比例28%,高于多西他赛组18%。
- 阿替利珠单抗组应答者中77%为长期生存者,多西他赛组应答者中仅48%。
- 阿替利珠单抗组21%的长期生存者最佳总疗效为疾病进展,长期生存不限于应答者。
核心结论
- 随访超过2年后,阿替利珠单抗对比多西他赛持续提供持久生存获益,且安全性可耐受。
- 阿替利珠单抗组长期生存者富集了PD-L1高表达患者,也包括PD-L1阴性患者。
- 长期生存不限于应答者。
研究设计与样本
- OAK(NCT02008227)为随机III期试验,患者按1:1随机接受阿替利珠单抗或多西他赛治疗,分别直至临床获益丧失或疾病进展。
- 在最少随访26个月后评估总生存,包括按最佳总疗效(BOR)定义的患者亚组。
- 长期生存者定义为自随机化起生存≥24个月的患者;非长期生存者为24个月内死亡者,24个月前删失的患者被排除于分析之外。
主要发现
- 在按最佳总疗效定义的所有患者亚组中均观察到阿替利珠单抗的生存获益。
- 阿替利珠单抗组长期生存者比例28%,高于多西他赛组18%。
- 阿替利珠单抗组应答者中77%为长期生存者,多西他赛组应答者中仅48%为长期生存者。
- 阿替利珠单抗组21%的长期生存者最佳总疗效为疾病进展(PD),且阿替利珠单抗组长期生存者较非长期生存者更多在疾病进展后继续治疗。
- 多西他赛组52%的长期生存者接受了免疫治疗作为后续非方案治疗(NPT)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atezolizumab (anti-programmed death-ligand 1 [PD-L1]) received approval from the US Food and Drug Administration and European Medicines Agency for previously treated advanced non-small-cell lung cancer based on OAK-a randomised, phase III trial that showed significantly improved survival with atezolizumab versus docetaxel regardless of PD-L1 expression. With longer follow-up, we summarised the characteristics of long-term survivors (LTSs). METHODS: In OAK (NCT02008227), patients were randomised 1:1 to receive atezolizumab or docetaxel until loss of clinical benefit or disease progression, respectively. Overall survival was evaluated after a 26-month minimum follow-up, including in patient subgroups defined by best overall response (BOR). LTSs were defined as patients who lived ≥24 months since randomisation. Non-LTSs died within 24 months, and patients censored before 24 months were excluded from the analysis. The baseline characteristics, including biomarkers, BOR, subsequent non-protocol therapy (NPT) and safety, are reported. RESULTS: Survival benefit with atezolizumab was observed across all patient subgroups defined by BOR. More atezolizumab-treated patients were LTSs versus those treated with docetaxel (28% versus 18%). Most atezolizumab responders were LTSs (77%) versus only 48% of docetaxel responders. However, 21% of atezolizumab-arm LTSs had progressive disease (PD) as BOR, and more atezolizumab-arm LTSs than non-LTSs continued treatment post-PD. Fifty-two percent of docetaxel-arm LTSs received immunotherapy as subsequent NPT. Despite extended treatment duration in atezolizumab-arm LTSs (median, 18 months), atezolizumab was well tolerated. CONCLUSIONS: After >2 years of follow-up, atezolizumab continued to provide durable survival benefit versus docetaxel, with tolerable safety. Atezolizumab-arm LTSs were enriched for patients with high PD-L1 expression and included PD-L1-negative patients. Long-term survival was not limited to responders.
引用
- von Pawel J, Bordoni R, Satouchi M, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2018. PMID: 30562710. doi:10.1016/j.ejca.2018.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。